DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials

Expert Opinion on Investigational Drugs

Volumn 16, Issue 6, 2007, Pages 855-866

  Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

(6 maleimidocaproyl)hydrazone derivative of doxorubicin; Anthracyclines; Anticancer prodrugs; Cancer chemotherapy; DOXO EMCH; Doxorubicin; Drug targeting

Indexed keywords

(6 MALEIMIDOCAPROYL)HYDRAZONE; ANGIOGENESIS INHIBITOR; APOLIPOPROTEIN; BR 96 DOXORUBICIN IMMUNOCONJUGATE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; DRUG CARRIER; ETOPOSIDE; FIBRONECTIN; FLUOROURACIL; INNO 206; LIPOSOME; METHOTREXATE; PK 1; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BODY WEIGHT; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PROTEIN BINDING; ECHOCARDIOGRAPHY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GOOD LABORATORY PRACTICE; HUMAN; IMMUNOTOXICITY; KIDNEY CARCINOMA; LD 50; LIPOSARCOMA; LIVER TOXICITY; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS;

ALBUMINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS; DOXORUBICIN; HUMANS; HYDRAZONES; NEOPLASMS; PRODRUGS;

EID: 34249980937     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.6.855     Document Type: Review

References (46)

1. GIANNI L, GRASSELLI G, CRESTA S et al.: Anthracyclines. Cancer Chemother. Biol. Response Modif. (2003) 21:29-40.
2. MINOTTI G, MENNA P, SALVATORELLI E, CAIRO G, GIANNI L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. (2004) 56(2):185-229.
3. SINGAL PK, ILISKOVIC N: Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. (1998) 339(13):900-905.
4. GIANNINI G: Fluorinated anthracyclines: synthesis and biological activity. Curr. Med. Chem. Anti-Cancer Agents (2002) 9(6):687-712.
5. ARCAMONE F, ANIMATI F, CAPRANICO G et al.: New developments in antitumor anthracyclines. Pharmacol. Ther. (1997) 76(1-3):117-124.
6. KRATZ F. WARNECKE A, SCHMID B, CHUNG DE, GITZEL M: Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem. - Anti-Cancer Agents (2006) 13(5):477-523.
7. KRATZ F, BEYER U, SCHÜTTE MT: Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier Sys. (1999) 16(3):245-288.
8. HAAG R, KRATZ F: Polymer therapeutics: concepts and applications. Angew Chem. Int. Ed. Engl. (2006) 45(8):1198-1215.
9. KRATZ F, BEYER U: Serum proteins as drug carriers of anticancer agents: a review. Drug Delivery (1998) 5:281-299.
10. BABSON AL, WINNICK T: Protein transfer in tumor-bearing rats. Cancer Res. (1954) 14(8):606-611.
11. MATSUMURA Y, MAEDA H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smarics. Cancer Res. (1986) 46(12 Part 1):6387-6392.
12. MAEDA H, WU J, SAWA T, MATSUMURA Y, HORI K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release (2000) 65:271-284.
13. STEHLE G, SINN H, WUNDER A et al.: Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. (1997) 26:77-100.
14. KRATZ F, ROTH T, FICHTNER I et al.: In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model. J. Drug Targeting (2000) 8(5)305-318.
15. KRATZ F, MUELLER-DRIVER R, HOFMANN I, DREVS J, UNGER C: A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. (2000) 43(7):1253-1256.
16. KRATZ F, WARNECKE A, SCHEUERMANN K et al.: Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. (2002) 45:5523-5533.
17. PETERS T. Serum albumin. Adv. Protein Chem. (1985) 37:161-245.
18. CARTER DC, HO JX: Structure of serum albumin. Adv. Protein Chem. (1994) 45:153-203.
19. FERGUSON E, SINGH RJ, HOGG N, KALYANARAMAN B: The mechanism of apolipoprotein B-100 thiol depletion during oxidative modification of low-density lipoprotein. Arch. Biochem. Biophys. (1997) 341(2):287-294.
20. SMITH DE, MOSHER DF, JOHNSON RB, FURCHT LT: Immunological identification of two sulfhydryl-containing fragments of human plasma fibronectin. J. Biol. Chem. (1982) 257(10):5831-5838.
21. SHIMOKAWA Y, ABE O, KUROMIZU K: Fluorescence labeling of a single sulfhydryl group in human plasma alpha 1-proteinase inhibitor and characterization of the labeled inhibitor. J. Biochem. (Tokyo) (1986) 100(3):563-570.
22. HULEA SA, OLINESCU R, NITA S, CROCNAN D, KUMMEROW FA: Cigarette smoking causes biochemical changes in blood that are suggestive of oxidative stress: a case-control study. J. Environ. Pathol. Toxicol. Oncol. (1995) 14(3-4):173-180.
23. WILLNER D, TRAIL PA, HOFSTEAD SJ et al.: (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem. (1993) 4:521-527.
24. KRATZ F, EHLING G, KAUFFMANN H, UNGER C: Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Human Exp. Toxicol. (2007) 26(1):19-36.
25. BERTAZZOLI C, ROVERO C, BALLERINI L et al.: Experimental systemic toxicology of 4′-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol. Appl. Pharmacol. (1985) 79(3):412-422.
26. BRISTOW MR, SAGEMAN WS, SCOTT RH et al.: Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J. Cardiovasc. Pharmacol. (1980) 2(5):487-515.
27. LEBRECHT D, GEIST A, KETELSEN U et al.: The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int. J. Cancer (2007) 120(4):927-934.
28. EKSBORG S, STENDAHL U, LONROTH U: Comparative pharmacokinetic study of adriamycin and 4′epi-adriamycin after their simultaneous intravenous administration. Eur. J. Clin. Pharmacol. (1986) 30(5):629-631.
29. MROSS K, MAESSEN P, VAN DER VIJGH WJ et al.: Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol. (1988) 6(3):517-526.
30. EKSBORG S, STRANDLER HS, EDSMYR F, NASLUND I, TAHVANAINEN P: Pharmacokinetic study of i.v. infusions of adriamycin. Eur. J. Clin. Pharmacol. (1985) 28(2):205-212.
31. SPETH PA, VAN HOESEL QG, HAANEN C: Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. (1988) 15(1):15-31.
32. TRAIL PA, WILLNER D, LASCH SJ et al.: Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 261(5118):212-215.
33. TRAIL PA, WILLNER D, KNIPE J et al.: Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res. (1997) 57(1):100-105.
34. TOLCHER AW, SUGARMAN S, GELMON KA et al.: Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. (1999) 17(2):478-484.
35. SALEH MN, SUGARMAN S, MURRAY J et al.: Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J. Clin. Oncol. (2000) 18(11):2282-2292.
36. AJANI JA, KELSEN DP, HALLER D, HARGRAVES K, HEALEY D: A multi-institutional Phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. (2000) 6(2):78-81.
37. DUNCAN R, COATSWORTH JK, BURTLES S: Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol. (1998) 17(2):93-104.
38. VASEY PA, KAYE SB, MORRISON R et al.: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. (1999) 5(1):83-94.
39. BILIM V: Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr. Opin. Mol. Ther. (2003) 5(3):326-330.
40. LOADMAN PM, BIBBY MC, DOUBLE JA, AL-SHAKHAA WM, DUNCAN R: Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin. Cancer Res. (1999) 5(11):3682-3688.
41. VAIL DM, AMANTEA MA, COLBERN GT et al.: Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. (2004) 31(6 Suppl. 13):16-35.
42. HARRINGTON KJ: Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin. Investig. Drugs (2001) 10(6):1045-1061.
43. GORDON AN, FLEAGLE JT, GUTHRIE D et al.: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. (2001) 19(14):3312-3322.
44. ROBERT NJ, VOGEL CL, HENDERSON IC et al.: The role of the liposomal an thracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol. (2004) 31(6 Suppl. 13):106-146.
45. EWER MS, MARTIN FJ, HENDERSON C et al.: Cardiac safety of liposomal anthracydines. Semin. Oncol. (2004) 31(6 Suppl. 13):161-181.
46. GABIZON A, SHMEEDA H, BARENHOLZ Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. (2003) 42(5):419-436.